Gatipotuzumab  (Synonyms: PankoMab)

Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

MUC1^[1]

Gatipotuzumab (PankoMab) strongly binds to a short MUC1 peptide of 30 amino acids comprising 1.5 TRs when it is glycosylated with GalNAcα at the T of the PDTRP-sequence, but not if the same peptide is not glycosylated^[2].
Gatipotuzumab (PankoMab) (1 h) has a high-affinity towards tumour cells (K_D of 0.91, 3.03, 3.84 and 7.14 nM towards NM-D4, ZR75-1, MCF-7 and T-47D, respectively)^[2].
Gatipotuzumab (PankoMab) (0-5 μg/mL; 4 h) shows specific anti-tumor antibody-dependent cell cytotoxicity activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

146560.00

1264737-26-9

Liquid

Colorless to light yellow

[Gatipotuzumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Mucin-1/MUC1 Protein, Human (269a.a, HEK293, His, HY-P78733) can bind Gatipotuzumab. The EC₅₀ for this effect is 26.65 ng/mL.

• [1]. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6.

  [2]. Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006 Nov;55(11):1337-47.  [Content Brief]